Table 3.
Effect of patient and medication characteristics on reasons for lipid-lowering medication dis-continuation
| Variable | Adverse reaction | Change requested by insurance | Ineffective | Other | Too expensive |
|---|---|---|---|---|---|
| Coronary artery disease | 0.9954 | 0.7559 (p = 0.0005) | 1.3169 | 0.8814 (p = 0.01) | 0.7646 (p = 0.0213) |
| Diabetes mellitus | 1.1108 | 1.8767 (p < 0.0001) | 1.5156 (p = 0.0239) | 1.3734 (p < 0.0001) | 1.1247 |
| Hypertension | 0.7722 (p = 0.0026) | 0.8187 (p = 0.0033) | 0.8343 | 0.7864 (p < 0.0001) | 1.0289 |
| Cerebrovascular accident | 0.8472 | 0.5641 (p < 0.0001) | 0.6302 | 0.6910 (p < 0.0001) | 0.6512 (p = 0.0257) |
| Peripheral vascular disease | 0.8678 | 0.8430 | 1.7480 (p = 0.026) | 0.9676 | 0.8029 |
| Income (by USD 1,000) | 1.0042 (p = 0.0271) | 0.9955 (p = 0.0058) | 1.0008 | 1.0044 (p<0.0001) | 1.0004 |
| Age | 0.9871 (p = 0.0014) | 0.9837 (p < 0.0001) | 0.9805 (p = 0.0017) | 0.9963 | 1.0111 (p = 0.0233) |
| History of multiple adverse reactions | 2.2178 (p < 0.0001) | 1.1533 (p = 0.0456) | 1.3363 (p = 0.0372) | 1.3224 (p < 0.0001) | 1.2450 (p = 0.0367) |
| Started before 2007 | 7.1225 (p < 0.0001) | 4.8321 (p < 0.0001) | 5.6271 (p < 0.0001) | 3.6238 (p < 0.0001) | 2.7541 (p < 0.0001) |
| CKD stage | |||||
| 3B | 0.9828 | 1.0391 | 0.9935 | 1.0893 | 1.0200 |
| 4 | 0.6692 (p = 0.0288) | 0.8599 | 0.5638 | 1.1063 | 0.8150 |
| 5 | 0.3905 (p = 0.0468) | 1.0767 | 0.5287 | 1.5639 (p = 0.0022) | 0.9435 |
| Gender (female)1 | 1.0185 | 0.9435 | 0.7689 | 0.8575 (p = 0.0005) | 0.9161 |
| Medication class | |||||
| Nonstatin | 4.3188 (p < 0.0001) | 0.9995 | 7.9365 (p < 0.0001) | 4.4924 (p < 0.0001) | 1.5237 (p = 0.0303) |
| Combo | 0.6092 (p = 0.0381) | 0.1545 (p < 0.0001) | 0.5691 | 0.4967 (p < 0.0001) | 0.2081 (p = 0.0002) |
| Insurance type | |||||
| Public | 1.4156 (p = 0.0007) | 1.3808 (p < 0.0001) | 1.1586 | 1.3487 (p < 0.0001) | 1.3631 (p = 0.0124) |
| Other | 1.5501 | 1.4658 | 0.5140 | 1.4230 | 1.7810 |
| Race2 | |||||
| Hispanic | 0.8072 | 1.6021 (p = 0.0002) | 1.2167 | 1.1349 | 1.1724 |
| African-American | 0.8216 | 1.2864 | 1.2723 | 1.25850.0235 | 1.4064 |
| Asian | 0.7153 | 2.1124 (p < 0.0001) | 1.7259 | 1.2534 | 0.8248 |
| Other | 0.9692 | 1.2920 | 1.95630.0119 | 1.32190.0097 | 1.94880.001 |
| Low-density lipoprotein value (by 10-unit increases) | 1.1481 (p < 0.0001) | 0.9981 | 1.1734 (p < 0.0001) | 1.0693 (p < 0.0001) | 0.9941 |
Effects of variables on reasons for discontinuation are represented by odds ratios. Medications that were not discontinued served as a reference. p values <0.05 are indicated in parentheses. Statistically significant estimates after adjustment for multiple hypothesis testing are given in bold.
1
Compared to male.
2
Compared to Caucasians.